Angle Share Discussion Threads

[bones698] 06/1/2024 09:15

Pj85 half that number as for every buy there is a sell traded . We might get a tr1 but there was a huge amount of traders buying and selling in there too . If someone is acquiring like an ii we should see continued buying Monday in blocks .

I see people still confusing myself with the other bones who is a sad individual who got upset because I called nanao right and he can't get over it . Just wanted to made some aware

[mrkeysersoze] 06/1/2024 09:00

Last sentence emphasised in bold to highlight what a few are not quite grasping , or choosing not too......."Another huge mover was Angle plc (up 145 per cent), which has developed a technology that draws a liquid biopsy that essentially tests for cancer by identifying microscopic circulating tumour cells.The company's latest innovation involves the expansion of its Parsortix system, which now includes DNA molecular analysis.This advancement allows for the detailed examination of both circulating tumour cells (CTCs) and fragments of DNA released by dying cells (ctDNA) from a single blood sample.In a recent study involving 47 patients with breast, lung, prostate and ovarian cancers, ANGLE's technology successfully identified key DNA mutations in CTCs that were not detected in ctDNA.This finding is particularly significant as it includes mutations that are targeted by FDA-approved cancer drugs, yet were missed by traditional ctDNA analysis"https://www.thisismoney.co.uk/money/markets/article-12930315/SMALL-CAP-MOVERS-C4X-Discovery-cashes-deal-pharma-giant.htmlMr K.

[gspanner] 06/1/2024 08:54

To add a bit more to Bermuda’s reply to bones about the sample size…

The sample size you need depends on the amount of difference the intervention makes. Small difference need large samples and vice versa. Here the potentially ‘drugable̵7; mutations are either present or absent so only a small size is needed.

What the study does not prove is whether the drugs described have more clinical benefit if used when present on the CTCs DNA rather than the ctDNA, which would require a bigger sample…. But also longitudinal monitoring so lots more Parsortix cassettes!

[pj84] 05/1/2024 22:30

Radders thanks, you are right, when I quickly looked I missed those, but following the reduction by Aegon in January, it looks like there hasn't been any major institutional selling since then, and as you point out Global Frontier were building a stake in January and March possibly picking up some shares from Aegon.

[radderssandy] 05/1/2024 22:11

Hi PJ, I also think we will get a TR-1 notification shortly.

There have been several other TR-1 notifications since October 2022. It’s just the RNS headings aren’t consistent. For example, the Global Frontier investments in January & March 2023 went under the RNS title “Holding(s) in Company”. I think the other TR-1’s were the sell notifications when Aegon & Ballie Gifford went under the share holding threshold.

[pj84] 05/1/2024 21:34

As some others have mentioned 85m shares traded over the last 2 days is about a third of the total shares of Angle and whilst some of the short-term traders will have both bought and sold over the last 2 days, and vice versa, so there will be some double counting in that figure. The volumes look far too high for just the day traders who have arrived and will soon depart when the volatility dies down as it will inevitably do so, and like others I expect we will get some new TR-1’s shortly.

I seem to recall AN saying that it was PI’s selling and causing the share price volatility and not the institutional shareholders and I have just had a quick look back and the last TR-1 appears to have been in Oct 22. So looking forward to any that may be issued next week.

[ic0gcds00] 05/1/2024 20:53

Remember covid and massive ramping re sng 13p-£3And look where it is nowAll angles in a much better space

[dealer55] 05/1/2024 20:43

Out of interest does anyone still use British Bulls.

[bones699] 05/1/2024 20:35

Simon

More like a very small gold fish bowl filled with very large hungry piranhas lol

[gooosed] 05/1/2024 19:46

Beg to differ - Bio/Med Tech M&A are forecast to be on a recovery trend in 2024 after a difficult few years. What better target than Angle ?

Having said that I hope they get to plough their own field but there's no room for sentiment & let's be brutally honest - the tech would reach & benefit more patients all the sooner as a result of a takeover. Angle are in a race to develop as much as they can in filling up the menu of content.

My hope is that they get to realise their potential - others will have their own preferences.

[bones699] 05/1/2024 19:41

Bermudashorts

"It's all about understanding the genetic mutations in a patients cancer, not diagnosis. They are using the same Illumina NGS gene panel for both ctDNA and CTCs and the results are what they are."

The purpose is to identify the cancer and then the suitable FDA approved drugs thereby providing earlier treatment, more effective treatment, and lower cost treatment.

Otherwise what is the purpose of understanding cancer genetic mutations if it is not to identify specific cancers in patients and treat them sooner with specific targeted treatment?

[purchaseatthetop] 05/1/2024 19:24

Nigelpm. Exactly. Spot on. The RNS opens potential doors but that is it. Any revenue could take years. It’s massive ramping on hopes. But good luck.

[nigelpm] 05/1/2024 19:19

Wild move this week - good news but people are getting way ahead of themselves.

[purchaseatthetop] 05/1/2024 19:16

Mrkeyser. Yes I sold at 60p. My views of AN mean that holders need to be very wary. I think that everybody should have a right to post if they are interested ESPECIALLY if they are not invested because therefore they are not pot committed.

You need to value views that ask questions, otherwise it is groupthink.

[bermudashorts] 05/1/2024 19:06

bones699

From you 22076:-

'how AGL can substantiate that a small sample of 47 patients supports the claim that 60% to 70% of patients cancers can be diagnosed'

What do you mean by the above? When have Angle ever claimed that this study was anything to with diagnosis of cancer? It's all about understanding the genetic mutations in a patients cancer, not diagnosis. They are using the same Illumina NGS gene panel for both ctDNA and CTCs and the results are what they are.

[mrkeysersoze] 05/1/2024 19:05

Patt,You used that same BS line years ago when you probably held, now you don't hold , questionable to say the least why you needed to postMr K.

[havinthelasttoast] 05/1/2024 18:58

A “research̶1; note came out the same day. New broker that week stated. Then news with a lot of innuendo.

No doubt newland is signing the placing as we speak. Dodgy rampers and their exit liquidity ramping. Got to laugh x

[dealer55] 05/1/2024 18:56

Sell and don’t buy then if concerned

[bones699] 05/1/2024 18:52

It will be interesting how AGL can substantiate that a small sample of 47 patients supports the claim that 60% to 70% of patients cancers can be diagnosed and specific FDA approved drugs prescribed when clinical tests require a far larger sample range running into hundreds if not thousands of tests to validate that the testing works over a long period of time and is not prone to a risk of failure or misdiagnosis. Which would be fatal if a misdiagnosis occurs and the wrong drugs are prescribed leading to the potential risk of fatalities and multi billion dollar lawsuits emerging in the USA...Equally has the FDA given formal approval this needs clarity as I belive its only granted 'research' approval only.

[dealer55] 05/1/2024 18:33

Zeus look at the day range you plank. That’s what I was talking about. 37-22 closing at 23.15.

That’s just wrong. Sure it could pull back after a big rise but people got played.

[purchaseatthetop] 05/1/2024 18:30

Sole trader. Very exciting. But a close relative works at Illumina in Cambridge. Thry have slashed their R@D spending and even cancelled most of their interns program this year. The tech is amazing. The timing may not be so. But good luck indeed.